71 results were returned
On 9 February 2021, the China National Intellectual Property Administration (“CNIPA”) issued the “Administrative Adjudication Measures for Drug Patent Dispute Early Resolution Mechanism (Draft for Public Opinions)” ...
Europe’s biotech industry is more buoyant now than it’s ever been.
A combination of eager investors, the high-speed development of COVID-19 vaccines, exciting scientific developments and last year’s acceleration of ...
On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical Industries Ltd. (“Teva”) – one of Bird & Bird’s key clients – is entitled to a preliminary injunction against ...
On 1 August 2019, the National Medical Products Administration ("NMPA") issued a notice to extend the pilot project of medical device registrant system (GUO YAO JIAN XIE ZHU (2019) No.33) ("Notice") to 21 ...
The NMPA issued the Drug Smart Supervision Plan aiming to deepen the development of a drug supervision system embracing modern information technologies such as cloud computing, big data, and "Internet+" technologies.
On 26 August 2019, China's National People's Congress passed the final amendments to the Drug Administration Law ("DAL"), which will take effect on 1 December 2019. The DAL was first enacted in 1984, then substantively ...
The Intellectual Property Enterprise Court (IPEC) has held that a patent was invalid but also considered a possible defence to infringement by equivalence.
On 10 November 2017, Henry Carr J in the English Patents Court delivered a significant decision which will be of great interest to litigants in the field of generic pharmaceuticals.
The Actavis v Eli Lilly decision of the UK Supreme Court has been described by some commentators as being a minor gloss on the law of patent infringement and claim scope.
Operating and establishing pharmacies has long been subject to strict regulations in Poland, for example anti-concentration requirements and the ban on advertising pharmacies.